JP5913103B2 - 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 - Google Patents

酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 Download PDF

Info

Publication number
JP5913103B2
JP5913103B2 JP2012529823A JP2012529823A JP5913103B2 JP 5913103 B2 JP5913103 B2 JP 5913103B2 JP 2012529823 A JP2012529823 A JP 2012529823A JP 2012529823 A JP2012529823 A JP 2012529823A JP 5913103 B2 JP5913103 B2 JP 5913103B2
Authority
JP
Japan
Prior art keywords
yeast
antigen
cell
based immunotherapy
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012529823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504623A (ja
JP2013504623A5 (https=
Inventor
ベルグラウ、ドナルド
タンブリーニ、ベス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of JP2013504623A publication Critical patent/JP2013504623A/ja
Publication of JP2013504623A5 publication Critical patent/JP2013504623A5/ja
Application granted granted Critical
Publication of JP5913103B2 publication Critical patent/JP5913103B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2012529823A 2009-09-14 2010-09-14 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 Active JP5913103B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US24235509P 2009-09-14 2009-09-14
US24235309P 2009-09-14 2009-09-14
US61/242,355 2009-09-14
US61/242,353 2009-09-14
US28856809P 2009-12-21 2009-12-21
US61/288,568 2009-12-21
PCT/US2010/048699 WO2011032119A1 (en) 2009-09-14 2010-09-14 Modulation of yeast-based immunotherapy products and responses

Publications (3)

Publication Number Publication Date
JP2013504623A JP2013504623A (ja) 2013-02-07
JP2013504623A5 JP2013504623A5 (https=) 2013-11-07
JP5913103B2 true JP5913103B2 (ja) 2016-04-27

Family

ID=43034390

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012529823A Active JP5913103B2 (ja) 2009-09-14 2010-09-14 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法

Country Status (6)

Country Link
US (3) US8911722B2 (https=)
EP (1) EP2477647B1 (https=)
JP (1) JP5913103B2 (https=)
AU (1) AU2010291985B2 (https=)
CA (1) CA2774326C (https=)
WO (1) WO2011032119A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097863A2 (en) 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
US8501167B2 (en) 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
MX350661B (es) 2011-03-17 2017-09-13 Us Health Composiciones inmunoterapeuticas de levadura-brachyuri.
CN103732250A (zh) 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2929351B1 (en) * 2012-12-10 2019-10-09 The University of Queensland Cell-free biofragment compositions and related systems, devices, and methods
AU2014265873B2 (en) 2013-03-19 2019-01-17 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
EP3308800B1 (en) * 2015-06-10 2021-08-25 The University of Tokyo Adjuvant for vaccines, vaccine, and immunity induction method
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
US20180250369A1 (en) * 2015-09-11 2018-09-06 Ventria Bioscience, Inc. Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
CA3152190A1 (en) * 2019-08-26 2021-03-04 The Brigham & Women's Hospital, Inc. Compositions and uses for engineered therapeutic microbes and associated receptors
EP4489774A4 (en) * 2022-03-08 2026-04-29 Immunitybio Inc YEAST-BASED VACCINE INJECTED INTRATUMORALLY

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4514506A (en) 1982-02-23 1985-04-30 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
CA2043472A1 (en) 1990-06-04 1991-12-05 Mitsutaka Miyabayashi Electrode for secondary battery
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5648226A (en) 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
JPH09502086A (ja) 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU1951001A (en) 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
KR101455222B1 (ko) 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2005086835A2 (en) 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
US20050239134A1 (en) 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
EP2460533A3 (en) * 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
WO2006124662A1 (en) 2005-05-13 2006-11-23 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
SG163572A1 (en) 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
JP2009510093A (ja) 2005-09-28 2009-03-12 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７ａおよびｉｌ−１７ｆアンタゴニストならびにその使用方法
PL1940465T3 (pl) 2005-10-26 2013-01-31 Novartis Ag Nowe zastosowanie przeciwciał anty-IL-1beta
WO2007111714A2 (en) 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
WO2007114861A2 (en) 2005-11-28 2007-10-11 Zymogenetics, Inc. Il-21 receptor antagonists
BRPI0619118A2 (pt) 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
US7736642B2 (en) 2006-02-02 2010-06-15 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
BRPI0709340A2 (pt) 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
MX2008013993A (es) 2006-05-03 2009-05-11 Univ Colorado Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
CN101563365B (zh) 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
EP2046835B1 (en) * 2006-08-11 2011-10-26 Schering Corporation Antibodies to il-17a
WO2008025032A1 (en) 2006-08-25 2008-02-28 Zymogenetics, Inc. Soluble il-27 receptor
WO2008025033A2 (en) 2006-08-25 2008-02-28 Zymogenetics, Inc. Use of il-27 antagonists for the manufacture of a medicament for the treatment of aplastic anemia
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
US20100150862A1 (en) 2006-12-07 2010-06-17 Schering Corporation Methods of modulating maternal-fetal tolerance
WO2008071685A1 (en) 2006-12-13 2008-06-19 Ablynx N.V. Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex
US8211420B2 (en) 2006-12-21 2012-07-03 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
WO2008097863A2 (en) 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
US8501167B2 (en) 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
GB0707505D0 (en) 2007-04-18 2007-05-30 Medical Res Council Antibodies against il-25
EP2150564A2 (en) 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009047360A1 (en) 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009100035A2 (en) 2008-02-01 2009-08-13 Wyeth Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3)
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EP2096438A1 (en) * 2008-02-28 2009-09-02 Martin Thurnher Methods for prognosing the status of patients
WO2009132821A1 (en) 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
US8178097B2 (en) 2008-05-23 2012-05-15 Wyeth Llc Methods of treatment utilizing binding proteins of the interleukin-21 receptor
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
EP2547792A4 (en) 2010-03-14 2013-11-27 Globeimmune Inc PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection

Also Published As

Publication number Publication date
CA2774326A1 (en) 2011-03-17
US20120321664A1 (en) 2012-12-20
HK1173672A1 (zh) 2013-05-24
EP2477647B1 (en) 2016-01-13
US8911722B2 (en) 2014-12-16
JP2013504623A (ja) 2013-02-07
CA2774326C (en) 2023-11-07
AU2010291985A1 (en) 2012-05-10
EP2477647A1 (en) 2012-07-25
US20190022197A1 (en) 2019-01-24
US10117915B2 (en) 2018-11-06
US20150196626A1 (en) 2015-07-16
AU2010291985B2 (en) 2016-05-05
WO2011032119A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
JP5913103B2 (ja) 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
RU2690180C2 (ru) Иммунотерапевтические композиции на основе дрожжей с brachyury
RU2642300C2 (ru) Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
JP5759980B2 (ja) 癌および感染症に対する免疫療法組成物の組み合わせ
KR102833272B1 (ko) 변형된 효모-브라큐리 면역치료학적 조성물
TW201514198A (zh) 治療或預防結核病的組合物及方法
HK1173672B (en) Modulation of yeast-based immunotherapy products and responses
KR20250089555A (ko) 면역요법 조성물 및 사용 방법
WO2025221993A1 (en) Compositions and methods for producing il-16
WO2025101276A1 (en) Compositions and methods for making and using immune cells
NZ724797B2 (en) Yeast-brachyury immunotherapeutic compositions
HK1192141A (en) Yeast-brachyury immunotherapeutic compositions
HK1192141B (en) Yeast-brachyury immunotherapeutic compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160401

R150 Certificate of patent or registration of utility model

Ref document number: 5913103

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250